SLU-PP-332 is often grouped with peptides online. Chemically, it is a synthetic small molecule. Every published in vivo efficacy study used intraperitoneal administration in mice, and the originating laboratory later developed SLU-PP-915 to solve SLU-PP-332’s lack of oral bioavailability.

That fact does not erase the preclinical findings. It defines them. The evidence supports ERR target engagement and animal-model outcomes under specific conditions. It does not establish that an oral SLU-PP-332 product reproduces injected mouse results.

The category error also affects documentation. Small-molecule identity, purity, metabolites, solubility, and pharmacokinetics require methods suited to that chemistry. A marketplace label or generic peptide-style certificate cannot answer those questions by appearance alone.